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Efficacy of Measles Vaccines after Controlling for Exposure 
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The clinical efficacy of measles vaccines was investigated in Niakhar, a rural area of 
Senegal under demographic surveillance in 1987-1 990. Three measles vaccines were 
tested: a standard Schwarz, a high-titer Edmonston-Zagreb, snd a high-titer Schwarz. 
The two high-titer vaccines were administered at 5 months a i  age and the standard 
Schwarz vaccine at 1 O months. In addition to aformal randomized vaccine trial, data from 
national campaigns using the standard Schwarz vaccine were also analyzed. Clinical 
efficacy was estimated after controlling for exposure. In the rûndomized trial, the esti- 
mate of the efficacy of the standard Schwarz vaccine was 97.2% (95% confidence 
interval (CI) 91.3-98.1). In the 1986-1 987 national campaign, the efficacy of the stand- 
ard Schwarz vaccine was lower: 92.5% (95% CI 88.8-94.6). In the randomized trial, the 
efficacy of the high-titer vaccines was lower than that of the standard vaccine. High-titer 
vaccines were not used in national campaigns. Other factors associated with vaccine 
efficacy were age at exposure, intensity of exposure, and age at vaccination. Controlling 
for the intensity of exposure did not change the relative ranking ofthe efficacy of the three 
vaccination strategies. The theoretical efficacy .of the standard measles vaccine for a 
single unit of exposure was estimated at 98.0%. Am J €pidemio/ 1993;138:182-95. 
child; measles; measles vaccine; multivariate analysis; population surveillance; pro- 
spective studies; rural population 
Measles is a leading cause of mortality 
and morbidity among children in developing 
countries (1, 2). Vaccination is the most ef- 
fective measure to control measles, and 
measles vaccination is recognized as one of 
the most cost-effective public health mea- 
sures. Recent studies have shown that mea- 
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sles vaccination has a major impact on child 
survival in developing countries (3, 4). 
However, the efficacy of the vaccines used 
in developing countries, which determines 
the impact of vaccination strategies, remains 
poorly documented. 
The further attenuated live measles vac- 
cines have been marketed in Western coun- 
tries since 1966 (5). After 1979, the major 
producers of measles vaccines introduced a 
new stabilization technique, the use of 
which may have increased the efficacy of 
the vaccines in the field (6).  These vaccines 
are usually referred to as “Schwarz vac- 
cines” in comparison with other vaccines, 
such as the Edmonston-Zagreb and the 
LeninFad- 16. which have been used pri- 
marily in the countries of the former Eastern 
block. 
Age at vaccination has been shown to be 
a major determinant of vaccine efficacy: 
children vaccinated too early do not sero- 
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convert and are not protected by the vaccine 
(7). The recommended age at vaccination 
with standard vaccines ranges from 12 to 15 
months in most Western countries, but in 
developing countries, it has been lowered to 
9 months to increase the protection of in- 
fants, who can contract measles as early as 
4 months of age (8). 
The recommended titer of measles vac- 
cines is at least 1,000 TCID,, (50 percent 
tissue culture infectious dose), as defined by 
the World Health Organization. Standard 
vaccines often contain 5,000-10,000 
TCID,,, although they have been shown to 
be efficient even with a titer as low as 20 
TCID,, (5). Studies conducted in The Gam- 
bia and in Mexico found that increasing the 
titer of the vaccine by 10- or 100-fold in- 
creased its immunogenicity and that the 
Edmonston-Zagreb strain produced better 
. seroconversion than the Schwarz strain. 
These results suggested that children could 
be vaccinated at 4-6 months of age with 
the high-titer Edmonston-Zagreb vaccine. 
I171 1990, the World Health Organization 
recommended the use of the high-titer 
Edmonston-Zagreb vaccine at 6 months of 
age in countries where measles was a sig- 
nificant cause of death in children less than 
9 months of age (9). 
There are several ways to estimate the 
clinical efficacy of vaccines: prospective or 
retrospective cohort studies, investigations 
of outbreaks, case-contact studies, and case- 
control studies. Estimates of vaccine efi-  
cacy depend on the following: the vaccine, 
its strain and titer, the age at vaccination, the 
intensity of exposure to measles during the 
study period, the interval between vaccina- 
tion and exposure, and the case definition of 
clinical disease and whether the exposure is 
similar among vaccinated and unvaccinated 
persons. In addition, in prospective studies, 
estimates of vaccine efficacy may depend on 
the duration of the study (10-12). 
Little is known about the efficacy of mea- 
sles vaccines in Africa, primarily because 
few extensive clinical trials have been con- 
ducted there. Therefore, most estimates of 
vaccine efficacy are derived from evalua- 
tions of national vaccination campaigns. 
Such estimates not only reveal. the efficacy 
of the vaccine, but also reflect the conditions 
under which the vaccines were adminis- 
tered, including failures in maintaining the 
vaccine at low temperature (the cold chain) 
and inappropriate age at vaccination. Fur- 
thermore, many of these estimates are based 
on suboptimal methodologies of data clol- 
lection. Estimates of efficacy range from 
less than 50 percent in the difficult condi- 
tions of Mozambique to 94.2 percent in 
Ivory Coast (13-17). The most reliable es- 
timates come from The Gambia, where an 
efficacy of 85.6 percent was found among 
children vaccinated at 9-14 months of age in 
a national campaign (13). 
This study reports the results of a 3-year 
clinical trial conducted in a rural area of 
Senegal. During this trial, the efficacy of 
three vaccination strategies was analyzed. 
Period efficacy was estimated directly by 
analyzing the incidence of clinical measles 
after vaccination. More important, case- 
contact efficacy was estimated by control- 
ling for exposure to measles in the com- 
pound (household) of residence, and a 
theoretical definition of efficacy after con- 
trolling for the intensity of exposure in the 
compound is presented. 
MATERIALS AND METHODS 
Study population 
The study area was located near Niakhar, 
in the département of Fatick in central Sene- 
gal. It comprises 30 villages whose total 
population includes about 25,000 people of 
Sereer origin. A comprehensive demo- 
graphic and epidemiologic surveillance sys- 
tem based on weekly visits to each com- 
pound of the study area and on the annual 
census was ongoing before the study began 
(July 1987) and has been maintained since 
that time. The demographic surveillance 
system recorded births, deaths, and in- and 
out-migration, and defined the resident pop- 
ulation at all points in time. The resident 
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population was divided into two categories: 
present or absent. Nonresidents who were 
present were called visitors. The epidemio- 
logic surveillance system routinely recorded 
the reported cases of measles every week for 
the present population (resident or visitor). 
In addition, the annual census recorded the 
reported cases of measles among those in the 
resident population who were absent at the 
time of infection. Therefore, two studies of 
vaccine efficacy were conducted: a prospec- 
tive period study of efficacy among the res- 
ident population (present or absent) and a 
case-contact study of efficacy in the com- 
pound among the present population (resi- 
dent or visitor). 
The efficacy study was part of a random- 
ized vaccine trial conducted from August 
1987 to July 1990 to compare two high-titer 
live measles vaccines, the Edmonston- 
Zagreb and the Schwarz, with the standard 
Schwarz vaccine with regard to efficacy, 
safety, and immunogenicity. The details of 
the vaccine trial and the main results con- 
cerning immunogenicity and safety have 
been reported (18-20). Since the measles 
surveillance system was based on the entire 
population, the study also provided the op- 
portunity to estimate the efficacy of the stan- 
dard Schwarz measles vaccine administered 
before the start of the study in the same vil- 
lages. 
The study was approved by the Sene- 
galese health authorities (Ministère de la 
Santé Publique, Dakar); by authorities of the 
Office de la Recherche Scientifique et Tech- 
nique Outre-Mer (ORSTOM) (Institut 
Français de Recherche pour le Développe- 
ment en Coopération, Paris, France); and by 
the ethical committee of the British Medical 
Research Council in Fajarah, The Gambia. 
During the 3 years of the project, compre- 
hensive vaccinations were made available to 
everyone, and free drugs and medical ser- 
vices were provided to all children and 
adults of the study population. As a conse- 
quence, both mortality and case fatality due 
to measles were significantly lower than 
during the preceding 3 years (1984-1986). 
Vaccinations 
Three series of vaccination were studied. 
Randomized trial of three vaccines. The 
randomized trial of high-titer measles vac- 
cines covered the cohorts of children born 
between February 1987 and January 1989. 
Children were randomized into three 
groups: high-titer Edmonston-Zagreb vac- 
cine administered at 5 months, high-titer 
Schwarz vaccine at 5 months, and standard 
Schwarz vaccine at 10 months. Randomiza- 
tion was done by allocating children just 
after birth to one of the three groups, using 
a random number generator. Children of the 
same birth cohorts who were not vaccinated 
were used as the control group. They were 
mostly children living under the same con- 
ditions who were not available on the day 
scheduled by the research team for the vac- 
cination. They did not differ in any socio- 
economic characteristic from the others. 
They were followed up in exactly the same 
way as the participants in the vaccine trial. 
For the participants, the age at vaccination 
was strictly standardized: 5.0 months 
(range, 18-28 weeks) for the high-titer vac- 
cines and 10.0 months (range, 40-47 weeks) 
for the standard vaccine. Only a few chil- 
dren received the standard vaccine after 10 
months of age. All three vaccines were sup- 
plied by the manufacturers: the high-titer 
Edmonston-Zagreb by the Institute of Im- 
munology, Zagreb, Yugoslavia (batch 8 1/3; 
titer, 5.4 log,, plaque-forming units (pfu)); 
the high-titer Schwarz by the Institut 
Mérieux, Lyon, France (batch 0980; titer, 
5.4 log,, pfu;); and the standard Schwarz by 
the Institut Mérieux, Lyon, France (titer, 3.7 
log,, pfu). The potency of the vaccines was 
monitored routinely and found to be con- 
stant over time. By January 1, 1990, 1,566 
children had been vaccinated; vaccine cov- 
erage was 8 1.6 percent of the resident target 
population. 
Monitored vaccination. A series of vacci- 
nations was organized and monitored by the 
principal investigator of this study in March 
of 1981, 1982, and 1983 in eight of the vil- 
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lages within the Primary Health Care Project 
(Ms. Irene Van Dyck, Coordinator). Stan- 
dard Schwarz vaccines from the Institut 
Mérieux were kindly furnished by Dr. 
Martin Schlumberger, the representative of 
the Association pour la Médecine Préven- 
tive (APMP, Paris, France) in Senegal. Strict 
control of the cold chain and vaccination 
procedure was observed. A total of 1,089 
children were vaccinated according to the 
guidelines of the Ministry of Public Health 
of Senegal, which recommended vaccinat- 
ing children between the ages of 9 and 23 
months. Vaccine coverage was 73 percent of 
the resident target population of children 
born between 1980 and 1982. Among them, 
386 were still resident at the time of the ef- 
ficacy study. 
National vaccination campaign and rou- 
tine vaccinations. A major national vacci- 
nation campaign took place from December 
1986 through April 1987. Records on health 
cards were taken during the demographic 
surveillance and checked in the dispensary 
registers whenever possible. The survey 
showed that 1,420 children born between 
1978 and 1986 and still resident during the 
efficacy study were vaccinated against mea- 
sles; the coverage was 44.1 percent among 
the cohorts born in 1984-1985. The demo- 
graphic census also routinely and system- 
atically recorded vaccinations done outside 
the study area by asking for health cards for 
all children under 15 years of age. Most of 
these routine vaccinations were given in 
large cities, where the child was traveling 
with his or her mother. Only a small number 
of children were in this group: 5.9 percent of 
the 1978-1986 cohorts. The measles vac- 
cines used in the routine vaccination cam- 
paigns were standard Schwarz vaccines 
from various Western producers. No attempt 
was made to find the exact producer. The 
potency of these vaccines at the time off in- 
jection and the quality of the cold chain 
could not be verified. Only a small propor- 
tion of the children (6.9 percent) were vac- 
cinated before the age of 9 months, the rec- 
ommended age at vaccination. 
Investigation of measles cases 
The three measles outbreaks occurring in 
the study area between August 1987 and 
July 1990 were investigated: 27 cases oc- 
curred between May and September 1988, 
161 cases between October 1988 and July 
1989, and 413 cases between August 1989 
and July 1990. When a family suspected a 
case of measles or when a case was seen in 
the clinic, a physician who was a permanent 
resident in the villages and specifically 
trained for this work was called to the com- 
pound to do a comprehensive clinical ex- 
amination, The physician monitored the 
measles cases by visiting the family twice a 
week until the last case was cured. The phy- 
sician was blind to the type of vaccine re- 
ceived during the vaccine trial, but was able 
to find out whether the child had been vac- 
cinated by asking the mother or the care- 
taker. For serologic confirmation, an initial 
blood sample was taken by finger prick from 
all susceptible children (those who had 
never had measles) in the family during the 
first visit, and a second sample was taken 
from the clinical cases at least 4 weeks after 
the onset of the r8ash. 
Exposure in compounds 
Exposure was defined as the condition of 
being susceptible and present in a compound 
of the study area where there was a clinical 
case. Secondary cases were defined as those 
occurring in the same compound 7-1 8 days 
after the index case. The mean time lag be- 
tween index and secondary cases was 12.2 
days, a value equivalent to that reported in 
classic studies (21-23). For both cases and 
noninfected contacts (susceptible children 
who were present), the following linear 
score of intensity of exposure to index cases 
was devised: 1 = living in a different com- 
pound; 2 = living in the same compound but 
not eating from the same kitchen; 3 = eating 
from the same kitchen but not sleeping in the 
same hut; and 4 = sleeping in the same hut 
(24). Other cases among the resident pop- 
ulation that occurred outside the study area 
were investigated primarily by questioning 
186 Garenne et al. 
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the family members; sometimes confirma- 
tion of a case was by record of a proper clin- 
ical examination found in a dispensary; 
other cases were confirmed by a blood sam- 
ple taken within a few weeks after the onset 
of the rash showing high levels of measles 
antibodies. However, these indirect pieces 
of evidence were not considered for final 
case validation. The surveillance system 
based on weekly visits to each compound 
and on systematic questioning during the an- 
nual census was very tight, and chances that 
a case was missed during the 3 years were 
very slim. 
Case definition 
A clinical score was defined by examining 
seven clinical signs observed during the 
physician's examination and summing up 
the values for each sign: 1) typical rash or 
desquamation (value = 6); 2) Koplik spot 
(value = 5); 3) atypical rash (value = 2); 
4) conjunctivitis (value = 2); 5) stomatitis 
(value = 2); 6) cough (value = 1); and 
7) rectal temperature greater than 38.0"C 
(value = 1). A reported case with a score of 
8 or more was considered clinically con- 
firmed. Of all reported cases, 80.1 percent 
were clinically confirmed; of reported cases 
examined during the 3-10 days after the on- 
set of clinical signs, 92.4 percent were clin- 
ically confirmed. 
Serologic confirmation was defined as an 
increase of at least fourfold in the titer of 
hemagglutination inhibition antibodies to 
measles virus during the acute phase. Of all 
the reported cases occurring before January 
1, 1990, 63.7 percent were serologically 
confirmed. Of all the reported cases whose 
first blood sample was taken before day 2 
and whose second blood sample was taken 
after day 28, 100 percent were serologically 
confirmed (n  = 112). All had at least a 16- 
fold increase in hemagglutination inhibition 
antibodies titer. The high confirmation rate 
from serology ensures that the clinical def- 
inition was highly specific in these circum- 
stances. Failure to obtain serologic confir- 
mation occurred when the family refused to 
i 
allow the blood sample, when the case was 
first investigated after the onset of the rash, 
or when the second blood sample could not 
be taken. 
A case was considered directly confirmed 
if it met both the clinical and the serologic 
criteria for confirmation. A case was con- 
sidered indirectly confirmed when it oc- 
curred in a compound where another case 
was directly confirmed. Altogether, 61.1 
percent of all reported cases were con- 
firmed, either directly or indirectly. The pro- 
portion of confirmed cases was higher 
among secondary cases in the compound 
(79.2 percent), since these were more likely 
to have been examined since the onset of the 
disease. Two definitions were used in the 
final analysis: reported cases and confirmed 
cases (direct or indirect confirmation). A 
vaccine failure was defined as a case of mea- 
sles in a child who was vaccinated at least 
14 days before the onset of the rash. 
Vaccine efficacy 
Vaccine efficacy was estimated by com- 
paring vaccinated children with unvacci- 
nated children who had never had measles 
before. As soon as a child had clinical mea- 
sles, he or she was removed from the pool 
of susceptible children. For the calculation 
of period efficacy, exact person-days at risk 
were computed for the resident population 
using dBASE IV (Ashton-Tate, Torrance, 
California). The starting point was 14 days 
after vaccination for vaccinated children or 
age 140 days (20 weeks) for unvaccinated 
children. The incidence rate was computed 
as the ratio of the cases to the person-years 
at risk lived by the susceptible population. 
Period efficacy was computed by the stan- 
dard formula: 1 - (incidence rate among vac- 
cinated children f incidence rate among un- 
vaccinated children). 
For calculation of the case-contact effi- 
cacy, exact exposure within the residence 
break. The secondary attack rate was com- 
puted as the ratio of secondary cases to the 
number of susceptible children exposed to 
compound was determined for each out- i 
i 
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the index cases in the compound. Case- 
contact efficacy was computed by the stan- 
dard formula: 1 - (secondary attack rate 
among vaccinated children + secondary at- 
tack rate among unvaccinated children). 
The 95 percent confidence intervals were 
computed using Taylor series approxima- 
tions when the sample was large (for period 
estimates of the campaigns) and asymptotic 
estimates when the sample was small. The 
later computations were performed with EPI 
]INFO (USD Inc., Stone Mountain, Georgia) 
Cl 1). 
RESULTS 
During the study period, a total of 601 
measles cases of all ages were investigated. 
Among them, 396 belonged to the cohorts 
kept for the final analysis, and 3 12 were sec- 
ondary cases among the same cohorts. 
exposed by the number at risk on January 1 , 
1990. For the randomized vaccine trial, the 
average exposure rate was 9.2 percent 
among children born between February 1, 
1987, and January 31, 1989, with no sig- 
nificant difference among the three vacci- 
nation groups. However, in the unvaccinated 
group, the exposure rate (13.2 percent) was , significantly higher (table 1). The exposure 
rate was also slightly higher (10.0 percent) 
among older children, i.e. those born be- 
tween 1978 and 1986. Differences in expo- 
sure rates between the two groups vacci- 
nated in national programs and the control 
group were significant, but of relatively 
small magnitude; in the group vaccinated 
during 1981-1983, the children were much 
older and the exposure rate was significantly 
lower (2.6 percent). 
Efficacy of standard vaccines 
Rate of exposure to measles Among children vaccinated with standard 
vaccines during the randomized trial, there 
The rate of exposure to measles in the 1 was only one case of vaccine failure, which 
was a secondary case (table 2). The period 
efficacy was 98.0 percent (95 percent con- 
study area during the investigation was com- 
puted by dividing the number of children 
TABLE 1. Study population and exposure to measles in compounids of the study area, according to  
vaccination status: Niakhar, Senegal, 1987-1 990 
Children 
Vaccination strategy No. resident 
on Mean age % exposed 
January 1, 1990 (years) 
Randomized trial of 3 vaccines in 30 villages, 1987- 
1989 (birth cohorts: 1987-1 989) 
Standard Schwarz at 1 O months of age 740 1.8 7.3* 
High-titer Edmonston-Zagreb at 5 months of age 552 1.8 9.6 
High-titer Schwarz at 5 months of age 274 2.3 8.8 
Controls (unvaccinated) 348 1.8 13.2t 
Monitored vaccination in 8 villages, 1981-1983 (birth 
Cohorts: 1978-1 982) I 
Standard Schwarz at 9-23 months of age 386 9.5 2.6" 
Other routine vaccinations with standard Schwarz 
vaccines (birth cohorts: 1978-1 986) 
National campaign of 1986-1 987 1,224 5.0 12.8" 
Other vaccinations, 1981-1989 720 8.1 7.2* 
Controls (unvaccinated) 4,403 7.3 1 o.ot 
* Sig,nificant difference from the controls, p < 0.05. 
t Reference categoty. 
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TABLE 2. Incidence and secondary attack rates of measles among the various groups of the 
susceptible population: Niakhar, Senegal, 1987-1990 
Case-contact study Prospective study 
Secondary 
Incidence No. of cases attack rate No. of cases 
per 1,000 reported/ per 1,000 reportedho. 
Group 
person-years no. confirmed children confirmed 
at risk 
Randomized trial of 3 vaccines in 30 villages, 
I 987-1 989 (birth Cohorts: 1987-1 989) 
Standard Schwarz at 10 months of age 0.80 1 /o 18.5 1 /o 
High-titer Schwarz at 5 months of age 6.67 512 83.3 2i1 
High-titer Edmonston-Zagreb at 5 months 
of age 4.12 513 56.6 312 
Controls (unvaccinated) 40.63 54/21 652.2 3011 3 
Monitored vaccination in 8 villages, 1981-1 983 
(birth Cohorts: 1978-1 982) 
Standard Schwarz at 9-23 months of age 1.22 1 /I 0.0 oí0 
Other vaccinations with standard Schwarz 
vaccines (birth cohorts: 1978-1 986) 
National campaign of 1986-1 987 4.56 1517 44.9 715 
Other vaccinations, 1981-1 989 5.14 8i3 96.2 512 
Controls (unvaccinated)* 33.62 30711 57 598.6 26411 O 1  
* Also used as the control group for the monitored vaccination. 
fidence interval (CI) 88.9-99.9), and the 
case-contact efficacy was 97.2 percent (95 
percent CI 91.3-98.1) (table 3, figure 1). 
There was no confirmed case among the 
cases of vaccine failure. Among children 
vaccinated in 1981-1983, there was only 
one case of vaccine failure, which was an 
index case. For this group, the period effi- 
cacy was 96.4 percent (95 percent CI 74.2- 
99.5) among reported cases and 92.9 percent 
among confirmed cases (95 percent CI 
49.4-99.0). Details of the computations can 
be derived from table 2 according to the def- 
initions given above. For instance, the pe- 
riod efficacy of 98.0 percent is obtained as 
The efficacy of standard vaccines was 
somewhat lower among children vaccinated 
during the national campaigns. Among the 
children vaccinated during the 1986-1987 
campaign, there were 15 cases of vaccine 
failure, five of them ,secondary cases. The 
period efficacy was 86.4 percent (95 percent 
CI 77.2-9 1.9), and the case-contact efficacy 
was 92.5 percent (95 percent CI 88.8-94.6). 
When the analysis was restricted to con- 
follows: 1 - (0.80 + 40.63). 
firmed cases, the values were 87.6 percent 
for period efficacy (95 percent CI 73.6- 
93.2) and 86.0 percent for case-contact ef- 
ficacy (95 percent CI 69.7-92.9). Among 
the children vaccinated elsewhere, there 
were eight cases of vaccine failure, two of 
them secondary cases. For this group, the 
period efficacy was 84.7 percent (95 percent 
CI 69.2-92.4), and the case-contact efficacy 
was 83.9 percent (95 percent CI 74.1-88.6). 
When the analysis was restricted to con- 
firmed cases, the corresponding values were 
88.8 percent for period efficacy (95 percent 
CI 64.9-96.4) and 83.2 percent for case- 
contact efficacy (95 percent CI 45.2-94.2). 
Efficacy of high-titer vaccines 
The efficacy of high-titer vaccines was 
studied only during the randomized trial 
and was found to be lower than the effi- 
cacy of the standard vaccine administered 
in the same cohorts. There were five vac- 
cine failures among children vaccinated 
with the high-titer Edmonston-Zagreb vac- 
cine; three of these were secondary cases. 
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TABLE 3. Clinical efficiency of measles vaccines: Niakhar, Senegal, 1987-1990 
Source of Period efficacy* Case-contact efficacy* 
vaccination and vaccine % 95% C l t  % 95% Cl? 
Randomized trial of 3 vaccines, 1987-1 989 
Standard Schwarz 
Reported cases 98.0 88.9-99.9 97.2 91.3-98.1 
Confirmed cases 100.0 80.0-1 00.0 100.0 78.0-100.0 
Reported cases 89.9 75.7-96.6 91.3 82.1-93.4 
Confirmed cases 84.4 47.9-96.8 86.6 49.1-95.3 
Reported cases 83.6 59.6-94.4 87.2 68.8-90.8 
Confirmed cases 83.1 31.9-97.7 85.3 14.4-95.81 
High-titer Edmonston-Zagreb 
Hiigh-titer Schwarz 
Monitored vaccination using standard Schwarz, 
1981-1983 
Reported cases 96.4 74.2-99.5 100.0 70.0-1 00.0 
Confirmed cases 92.9 49.4-99.0 100.0 0.0-100.0 
National campaign using standard Schwarz, 1986-1 987 
Reported cases 86.4 77.2-91.9 92.5 88.8-94.6 
Confirmed cases 87.6 73.6-94.2 86.0 69.7-92.9 
Other routine vaccinations using standard Schwarz, 
1981-1 989 
Reported cases 84.7 69.2-92.4 83.9 74.1-88.6 
Confirmed cases 88.8 64.9-96.4 83.2 45.2-94.2 
* Directly computed from table 2; see "Vaccine efficacy" under "Materials and Methods" for details. 
t CI, confidence interval. 
In addition, there were five failures among 
childr'en vaccinated with the high-titer 
Schwarz vaccine, two of them secondary 
cases. The period efficacy 'of the high-titer 
Edmanston-Zagreb vaccine was 89.9 per- 
cent ('95 percent CI 75.7-961.6) and the case- 
100.0 
95.0 
90.0 
s 80.0 
75.0 
.z 70.0 
p 
5 85.0 
65.0 .- 
60.0 - -  
55.0 * -  
contact efficacy was 91.3 percent (95 per- 
cent CI 82.1-93.4) (t,able 3). When the. 
analysis was restricted to confirmed c8ases, 
the corresponding values were 84.4 per- 
cent (95 percent CI 47.9-96.8) for period 
efficacy and 86.6 (95 percent CI 49.1- 
Standard Standard EZ-HT SW-HT 
(10 mo) (varia) (5 mo) (5 "1 
Vaccination strategy 
FIGURE 1. Clinical efficacy of measles vaccines, Niakhar, Senegal, 1987-1989, (vertical bars show 95% confi- 
dence interval). Children in the second group were vaccinated at various ages (varia) above 9 months, whereas 
children in other groups were vaccinated at the exact age of 5 or 10 months. (Standard, standard Schwarz vaccine; 
EZ-HT, high-titer Edmonston-Zagreb vaccine; SW-HT, high-titer Schwarz vaccine. The age in months (mo) at which 
the vaccine was administered is given below the name of the vaccine.) 
a ' i  
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TABLE 4. Estimates of the theoretical case-contact efficacy of three measles vaccines in a randomized 
trial, from linear logistic regression controlling for intensity of exposure: Niakhar, Senegal, 1987-1990 
Results of the linear logistic model* 
Covariate Theoretical Relative 
Estimatest 
efficacy failure 
High-titer Edmonston-Zagreb vaccine 0.020 0.005-0.236 0.944 2.82 
High-titer Schwarz vaccine 0.053 0.001-0.272 0.861 7.06 
Intensity of exposure 
OR* 95% CI* 
Standard Schwarz vaccine 0.007 0.001-0.1 17 0.980 1 .o0 
2.291 1 .I 25-4.667 
* The reference group are unvaccinated children exposed in the same conditions in the household. 
t See text and appendix for computations of theoretical efficacy. The relative failure is equal to the ratio of the failure rate after 
a high-titer vaccine given at 5 months of age to the failure rate afterthe standard Schwarz vaccine given at 10 months of age (reference 
category). * OR, odds ratio; CI, confidence interval. 
95.3) for case-contact efficacy. The period 
efficacy of the high-titer Schwarz vaccine 
was 83.6 percent (95 percent CI 59.6- 
94.4) and the case-contact efficacy was 
87.2 percent (95 percent CI 68.8-90.8). 
When the analysis was restricted to con- 
firmed cases, the corresponding values 
were 83.1 percent (95 percent CI 39.9- 
97.7) for period efficacy and 85.3 (95 per- 
cent CI 14.4-95.8) for case-contact effi- 
cacy. 
Control for intensity of exposure 
A linear logistic model was developed to 
control for the intensity of exposure to mea- 
sles. The dependent variable was the sec- 
ondary attack rate and the independent vari- 
ables were the vaccine and the intensity of 
exposure. Once exposure to measles oc- 
curred in a compound, the mean intensity of 
exposure among vaccinated (3.21) and un- 
vaccinated (3.18) children was not signifi- 
cantly different ( p  = 0.581). The results in- 
dicate that the intensity of exposure was a 
major determinant of secondary infection in 
the family (table 4). The odds ratio was 2.3 
per unit of exposure; assuming an exposure 
rate of 8.0 percent, this is equivalent to a 
relative risk of 2.1, which can be interpreted 
as a 4.4 times greater risk of infection from 
sleeping in the same hut with an index case 
than from living in the same compound with 
an index case. Similar values of relative 
risks associated with intensity of exposure 
were found for the vaccinated and unvac- 
cinated children. There was no significant 
interaction between the vaccine and the in- 
tensity of exposure ( p  = 0.967): 
Controlling for intensity of exposure in 
the logistic regression allows one to define 
a theoretical efficacy for a minimal unit of 
exposure. Details of the derivations are 
given in the Appendix. The theoretical case- 
contact efficacy of the standard vaccine was 
98.0 percent, as compared with 94.4 percent 
for the high-titer Edmonston-Zagreb vac- 
cine and 86.1 percent for the high-titer 
Schwarz vaccine. In other words, control- 
ling for intensity of exposure did not change 
the ranking of the vaccination strategies. 
There were 2.8 times more vaccine failures 
among those who received the high-titer 
Edmonston-Zagreb vaccine at 5 months of 
age and 7.1 times more failures among those 
who received the high-titer Schwarz vaccine 
at 5 months of age than there were among 
those who received the standard vaccine at 
10 months of age. 
TABLE 5. Factors of the theoretical case-contact 
efficacy of standard measles vaccines in national 
campaigns, from linear logistic regression*: 
Niakhar, Senegal, 1987-1990 
Covariate ORt 95% Cl? 
Vaccination (standard) 0.021 0.006-0.084 
Age at exposure 
(1 -year increase in age) 1 .O88 1 .OOO-1.183 
Intensity of exposure (4 units) 3.532 1.149-1 0.83 
Vaccination 5 months earlier 
(if before age 12 months) 3.467 1.015-11.76 
Vaccination 1 O years earlier 2.709 0.204-36.13 
* The reference group are unvaccinated children exposed in 
t OR, odds ratio; CI, confidence interval. 
the same conditions in the household. 
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Factors associated with the efficacy of 
standard vaccines 
Several factors associated with the effi- 
cacy of standard vaccines in national cam- 
paigns were analyzed in a similar linear lo- 
gistic regression. The dependent variable 
was the secondary attack rate among chil- 
dren bom between 1978 and 1986, and the 
four independent variables were age at ex- 
posure, intensity of exposure, an indicator of 
age at vaccination (the number of months 
before 12 months of age), and the time 
elapsed since vaccination (table 5). Two 
other variables were also analyzed but not 
found to be significant: the sex of the child 
and the vaccination campaign in which he ar 
she was vaccinated. The results showed the 
same theoretical efficacy in the vaccination 
campaigns as in the randomized trial (97.9 
percent, 95 percent CI 91.6-99.5). Age at 
exposure was found to be a significant risk 
factor for vaccine failure, with a relative risk 
of 1.088 per year of age. Intensity of expo- 
sure was significant, with a relative risk of 
vaccine failure of 3.53 for maximal expo- 
sure (i.e., sleeping in the same hut). Vacci- 
nation before 12 months of age had a sig- 
nificant effect on vaccine failure, with a 
relative risk of 1.28 per month. Vaccination 
5 months earlier multiplied the risk of vac- 
cine failure by 3.47 (95 percent CI 1.01- 
11.9), a value similar to the relative failure 
rate of high-titer vaccines given at 5 months 
compared with standard vaccines given at 
10 months in the randomized trial. This find- 
ing indicates that the potential gain of using 
high-titer vaccines early in life was mar- 
ginal. The time elapsed since vaccination, 
which measures waning immunity, was not 
significant when all other factors were con- 
trolled for in the regression. 
DISCUSSION 
Several studies have provided estimates 
of the clinical efficacy of standard vaccines 
in North America (6, 8,25,26), They show 
a median estimate of 96.0 percent for clin- 
ical protection, with a range from 93.2 to 
96.9 percent. Two factors having an impact 
on efficacy were identified: the age at vac- 
cination (before or after 15 months) and the 
type of vaccine (produced before or after 
1979). Most of these estimates were derived 
from case-contact studies or retrospective 
cohorts among children in school or college 
after exposure during an outbreak. Similar 
results were found in Europe. A study con- 
ducted in England and Wales produced an 
estimate of 93.1 percent during a 21-year 
follow-up of children vaccinated at 10-23 
months of age with a Schwarz vaccine, a rate 
equivalent to 97.0 percent efficacy on a sin- 
gle exposure (27). In France, a study found 
a vaccine efficacy of 94.6 percent in a 4-year 
period among children vaccinated at 12-23 
months with a Schwarz vaccine a rate equiv- 
alent to 95.5 percent on a single exposure 
(28). A study of the Edmonston-Zagreb vac- 
cine conducted in three sites in Yugoslavia 
found an efficacy of 97.3 percent among 
children vaccinated at 10 months of age or 
older. When properly administered, measles 
vaccines seem to protect about 96 percent of 
children against clinical measles. 
The estimates of vaccine efficacy found in 
Senegal were very close to these values 
found in developed countries. They can be 
taken as the standard against which the ef- 
ficacy of measles vaccines in other contexts 
is evaluated. Note that the efficacy of mea- 
sles vaccines remains very satisfactory, 
much higher than that of some other vac- 
cines (pertussis, influenza) and close to that 
of the best vaccines available (tetanus, yel- 
low fever). The estimates of vaccine effi- 
cacy from the randomized trial were higher 
than most estimates reported from develop- 
ing countries. This may reflect differences in 
the quality of vaccine delivery, in particular 
the quality of the cold chain and the precise 
age at vaccination. 
The data set gathered during this study 
is virtually unique in tropical Africa. There 
is a high degree of consistency among the 
estimates of efficacy faund in this study 
, 
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and also between these estimates and other 
estimates of the efficacy of measles vac- 
cines. In particular, the efficacy of stan- 
dard vaccines observed in this clinical trial 
compares closely with the values found in 
developed countries. This result indicates 
that there is no reason to think that stan- 
dard measles vaccines, when properly ad- 
ministered, are less efficacious in Africa 
than in the developed countries. 
To our knowledge, there is no other pub- 
lished empirical study estimating vaccine 
efficacy after controlling for intensity of ex- 
posure to which these results could be com- 
pared. However, that intensity of exposure 
influences the estimate of vaccine failure 
makes sense. It suggests that accurate com- 
parisons of vaccine failure require a proper 
description of exposure, a point that has 
been discussed extensively in the theoretical 
literature (12). 
Controlling for exposure further validated 
the estimates. None of the vaccinated groups 
had a randomized control group of unvac- 
cinated children, and in fact, it would not 
have been ethical to design a study with a 
control group of this kind. Although the con- 
trol groups were similar to the vaccinated 
groups in many respects, their rate of ex- 
posure was 13 percent higher'(95 percent CI 
1 .OO-1.30, p = 0.05 1). Although small, this 
could bias the estimates of period efficacy. 
However, controlling for exposure allowed 
precise estimates of case-contact efficacy, 
which can be considered the most reliable 
estimate. 
Controlling for intensity of exposure did 
not change the order of magnitude of the 
relative estimates of vaccine failure. A linear 
score of intensity of exposure was used, 
which translates into a proportional odds ra- 
tio of vaccine failure in the logistic regres- 
sion. The choice of the linear score was jus- 
tified by a preliminary analysis of the values 
of the relative secondary attack rates for 
three increasing values of the level of in- 
tensity of exposure, both for cases among 
unvaccinated children (1 .OO, 1.50, and 1.83) 
and cases among vaccinated children (1 .OO, 
1.15, and 1.55). Although not perfect, the 
log-linear assumption was considered ac- 
ceptable for the multinomial regression. 
The efficacy of the standard Schwarz vac- 
cines was higher in the clinical trial than 
after the national campaigns. The rate of 
vaccine failure after the national campaigns 
was 5.2 times greater than that observed in 
our clinical trial using the same standard 
vaccine. This result was expected, insofar as 
failures in the cold chain are common in large- 
scale campaigns. The efficacy of vaccines in 
national vaccination campaigns of Senegal 
compares closely with values found nearby 
in The Gambia (13). 
Estimates of period efficacy were simi- 
lar to those of case-contact efficacy. This 
result was expected, since multiple expo- 
sures were unusual during the study period 
(10.1 percent of cases), and the period of 
follow-up was relatively short. The small 
differences in exposure during the period 
of the study had virtually no impact on the 
period estimates, which were obtained by 
use of precise periods of exposure to risk 
within the susceptible population. This 
procedure leads to an unbiased estimate of 
vaccine efficacy as defined by a propor- 
tionate reduction in incidence at each ex- 
posure (10). This choice was justified by 
the very probabilistic nature of vaccine 
failure found in the effect of intensity of 
exposure. However, if efficacy had been 
defined as the proportion of the population 
that was fully protected, this procedure 
would lead to an overestimation of effi- 
cacy that increases with time. In this case, 
theoretical computations show that expo- 
sure for 3 years leads to a small overesti- 
mation of period efficacy: an observed ef- 
ficacy of 98.0 percent would be equivalent 
to a theoretical efficacy of 97.7 percent, a 
small difference given the confidence in- 
terval of the point estimate. 
Measles cases among vaccinated children 
were less likely to be confirmed than those 
among unvaccinated children, because in 
vaccinated children, the clinical effects of 
the disease were milder and the elevation of 
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antibodies lower (18). In fact, only 53.3 per- 
cent of the cases that occurred after failure 
of a vaccine were confirmed, compared with 
67.4 percent of cases that occurred among 
unvaccinated children. This situation led to 
an artificially high estimate of vaccine ef- 
ficacy among confirmed cases. The theoret- 
ical computations give an expected bias of 
21 percent for vaccine failure, which re- 
mains consistent with the overall empirical 
findings. However, the differences between 
estimates of efficacy among all cases and 
among confirmed cases varied in each of the 
three vaccination series, depending on the 
proportion of cases confirmed in each 
group. 
The comparison of the two trials using the 
standard Schwarz vaccine showed that 80 
percent more failures occurred 10 years after 
vaccination (198 1-1983) than occurred 2 
years after vaccination (1987-1989). In the 
study of the duration since vaccination as a 
risk factor for vaccine failure, the risk ratio 
for 10 years after vaccination as compared 
with 1 year after vaccination was 2.71. How- 
ever, none of these differences was statisti- 
cally significant. 
In the clinical trial setting, the failure 
rate of the high-titer vaccines was some- 
what higher than that of the standard vac- 
cines, even after exposure had been con- 
trolled for, The differences were not 
significant in this study, but they were 
found to be significant after the level of 
maternal antibodies at time of vaccination 
was controlled for (20). The failure rate of 
the high-titer Schwarz vaccine was higher 
than that of the high-titer Edmonston- 
Zagreb vaccine, an observation that 
matches the observed differences in sero- 
conversion rates after administration of 
these two vaccines (29, 30). Because of 
the small numbers, the efficacy of the high- 
titer Edmonston-Zagreb vaccine betwleen 
the ages of 5 and 10 months among chil- 
dren to whom it was administered at 5 
months was not significantly different 
from zero ( p  = 0.147) when compared 
with the randomized control group that re- 
ceived a placebo at 5 months (18). There 
was no case of vaccine failure in the high- 
titer Schwarz group between the ages of 5 
and 10 months, and therefore, vaccine effi- 
cacy could not be computed for this age 
group. If the risk ratios for vaccine failure 
in national campaigns were equivalent to 
those found for the standard vaccine, then 
the failure of high-titer vaccines given at 5 
months of age could be as high as 50 per- 
cent in general use. 
In the randomized trial, both clinical ef- 
ficacy and seroconversion were negatively 
correlated with the level of maternal anti- 
bodies at the time of vaccination. Another 
paper addresses this issue in detail (20). 
The rationale behind the use of high-titer 
vaccines was earlier vaccination of infants 
to avert a number of measles cases that occur 
between the ages of 6 and 9 months. How- 
ever, the higher failure rate associated with 
high-titer vaccines balanced the earlier pro- 
tection. Assuming a constant incidence of 
measles of O. 1 case per person per year, sus- 
ceptibility to measles starting at 4 months of 
age, and the values of clinical efficacy ob- 
served in this trial, a cohort of 1,000 children 
would experience 373 cases of measles by 
the age of 5 years if no one was vaccinated, 
87 cases if all infants were vaccinated with 
the high-titer Schwarz vaccine at 6 months 
of age, 60 cases if all infants were vacci- 
nated with the high-titer Edmonston-Zagreb 
vaccine at 6 months of age, and 57 cases if 
all infants were vaccinated with the standard 
vaccine at 9 months of age. Therefore, in 
theory, the high-titer strategy would not be 
optimal for preventing clinical measles be- 
tween birth and 5 years of age. The situation 
would be even worse if all ages up to 30 
years were taken into consideration. How- 
ever, in practice, the decreasing efficacy 
might be compensated for by an increasing 
vaccination coverage usually associated 
with a lower age at vaccination in develop- 
ing countries. 
Furthermore, the high-titer vaccines are 
more costly to produce than the standard 
vaccine, a factor that lowers their cost- 
194 Garenne et al. 
effectiveness. Finally, the high-titer vac- 
cines have been found to significantly in- 
crease children's risk of death within 3 years 
of vaccination (19). This finding was con- 
firmed by two other studies and led to a 
change in the recommendations of the World 
Health Organization (31). This differs mark- 
edly from the standard vaccines, which have 
been shown to dramatically reduce child- 
ren's risk of death in a similar environment 
(3). The results of this study emphasize the 
importance of studies based on a compre- 
hensive surveillance of well-defined popu- 
lations. 
Although imperfect, vaccination with 
standard vaccines at 9 months of age re- 
mains a sound strategy. If well implemented 
with a high coverage rate, it could produce 
herd immunity and thereby reduce the in- 
cidence of disease before the recommended 
age at vaccination (9 months). Together with 
the appropriate management of measles 
cases, this strategy could in theory lead to 
satisfactory control of measles mortality 
(18). However, there is still a need for al- 
ternative strategies in order to protect chil- 
dren as soon as they become susceptible, for 
instance, with more immunogenic vaccines, 
or with several doses given at various ages. 
New and more efficient strategies could also 
open the way to global eradication. 
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APPENDIX 
Computation of theoretical efficacy from logistic regression 
Notations: 
SAR, = secondary attack rate among vaccinated children 
SARO = secondary attack rate among unvaccinated children 
TVE = theoretical vaccine eficacy 
Logistic equation: 
SARoI(l - SARO) = exp(a) 
SAR,I(l - SAR,) = exp(a + b,) 
TVE = 1 - SARJSAR, 
SAR,I(l - SAR,) = exp(b,) X SARoI(l - SARO) 
Therefore: 
SAR,ISAR, = exp(b,)/[(l - SARO) + exp(b,) X SARO] 
TVE = 1 - exp(b,)/{l - SARO X [l - exp(b,)]} 
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